BRCA1 and breast carcinoma: The phase III OlympiA trial, which demonstrated increased survival with olaparib for patients with early-stage BRCA1/2-mutated breast cancer, administered olaparib after the completion of adjuvant radiation therapy, thus providing no information on the safety of concurrent treatment.3